Clinic
Access Pain Solutions
Access Pain Solutions was paid $13.10M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 26% of everything it billed.
33Billing provider infoACCESS PAIN SOLUTIONS
TULSA, OK 74146
TULSA, OK 74146
33aNPI1740535368assigned 07/19/2012
33bProvider typePrimary Care Clinic/Center
28Total paid$13.10M
24GClaims342,407
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Oklahoma
Rank by total paid#1 of 86
Median peer was paid$175K
This provider vs. median75×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,522 | $1.06M | |
| 2019 | 32,463 | $1.22M | |
| 2020 | 32,941 | $1.25M | |
| 2021 | 45,308 | $1.81M | |
| 2022 | 70,871 | $2.71M | |
| 2023 | 72,101 | $2.80M | |
| 2024incomplete | 58,201 | $2.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 26% | 61,781 | 59,428 | $3.38M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 64,472 | 62,353 | $3.20M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 22,580 | 22,182 | $1.64M |
| 64635 | 4.4% | 1,919 | 1,792 | $582K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.0% | 4,720 | 4,716 | $525K |
| 64636 | 3.0% | 1,668 | 1,550 | $399K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.0% | 2,331 | 2,329 | $395K |
| 80050 | General health panel | 2.6% | 10,592 | 10,546 | $343K |
| 96127 | 2.0% | 67,969 | 65,841 | $264K | |
| 99406 | 1.8% | 17,868 | 17,365 | $237K | |
| 64493 | 1.7% | 1,380 | 1,247 | $227K | |
| J0475 | Injection, baclofen, 10 mg | 1.3% | 407 | 403 | $168K |
76 more codes
| 64483 | 1.3% | 842 | $165K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 5,804 | $154K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,226 | $118K |
| 64494 | <1% | 1,181 | $101K | |
| 62323 | <1% | 526 | $90K | |
| 80061 | Lipid panel | <1% | 7,040 | $85K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,081 | $80K |
| 82607 | <1% | 5,514 | $74K | |
| 84403 | <1% | 3,087 | $73K | |
| 99152 | <1% | 3,732 | $70K | |
| 84402 | <1% | 2,570 | $60K | |
| 62321 | <1% | 271 | $51K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 4,654 | $42K |
| 82627 | <1% | 2,095 | $42K | |
| 84270 | <1% | 2,161 | $41K | |
| 64633 | <1% | 124 | $36K | |
| 83970 | <1% | 756 | $31K | |
| 84480 | <1% | 2,455 | $31K | |
| 82670 | <1% | 1,019 | $29K | |
| 82746 | <1% | 1,920 | $26K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 185 | $24K |
| 64495 | <1% | 216 | $23K | |
| 20610 | <1% | 501 | $22K | |
| 64490 | <1% | 124 | $22K | |
| 80400 | <1% | 713 | $20K | |
| 62369 | <1% | 479 | $20K | |
| 84436 | <1% | 3,082 | $19K | |
| 64634 | <1% | 70 | $18K | |
| 86140 | <1% | 3,471 | $16K | |
| 84234 | <1% | 248 | $16K | |
| 84481 | <1% | 935 | $15K | |
| 83001 | <1% | 670 | $12K | |
| 83002 | <1% | 665 | $12K | |
| 82533 | <1% | 850 | $12K | |
| 84439 | <1% | 1,413 | $12K | |
| 77002 | <1% | 175 | $11K | |
| 64491 | <1% | 99 | $9K | |
| 84146 | <1% | 349 | $7K | |
| 62370 | <1% | 158 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,710 | $6K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 788 | $6K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 875 | $5K |
| 83735 | <1% | 646 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 58 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 336 | $4K |
| 83615 | <1% | 583 | $4K | |
| 84144 | <1% | 140 | $3K | |
| 99490 | Ccm add 20min | <1% | 848 | $3K |
| 82728 | <1% | 207 | $3K | |
| 84153 | <1% | 162 | $3K | |
| 64492 | <1% | 29 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 218 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 98 | $2K |
| 84100 | <1% | 324 | $2K | |
| 82248 | <1% | 300 | $2K | |
| 84550 | <1% | 312 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 120 | $1K |
| 64450 | <1% | 26 | $936.42 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,355 | $847.77 |
| 76942 | <1% | 16 | $558.98 | |
| 84479 | <1% | 52 | $341.89 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,532 | $249.56 |
| 84450 | <1% | 45 | $236.70 | |
| 82550 | <1% | 39 | $228.90 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 76 | $169.18 |
| 84460 | <1% | 26 | $139.88 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17 | $125.97 |
| 82040 | <1% | 30 | $124.78 | |
| 82247 | <1% | 18 | $91.62 | |
| 82310 | <1% | 17 | $89.08 | |
| 84132 | <1% | 18 | $84.06 | |
| 84075 | <1% | 13 | $68.38 | |
| 82947 | <1% | 16 | $63.84 | |
| 84155 | <1% | 17 | $63.41 | |
| J2704 | Injection, propofol, 10 mg | <1% | 172 | $15.08 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 20 | $0.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFERRELL, CANNEN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Access Medical Affordable Family Healthcare, LLC | Tulsa, OK | $2.00M |
| Access Solutions Medical Group II | Okmulgee, OK | $1.07M |
| Dermatology & Allergy Solutions LLC | Broken Arrow, OK | $26K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.